CTOs on the Move

True North Therapeutics

www.truenorthrx.com

 
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

True North Therapeutics raised $40M on 12/03/2015
True North Therapeutics raised $45M on 10/19/2016

Similar Companies

Atmofizer

The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.

Tioma Therapeutics

Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.

Bioforward

Bioforward is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nutripro Biosystems

Nutripro Biosystems is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angiocrine Bioscience

Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs